Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia G Silber

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
American Journal of Obstetrics and Gynecology|January 27, 2005
Board certification in obstetrics and gynecology: associations with physicians' demographics and performances during medical schoolCynthia G Silber, J Jon Veloski
Academic Medicine : Journal of the Association of American Medical Colleges|May 29, 2004
Do global rating forms enable program directors to assess the ACGME competencies?Cynthia G Silber, Thomas J Nasca, David L Paskin, et al.
European Urology Oncology|July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialBrian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
American Journal of Obstetrics and Gynecology|January 27, 2005
Board certification in obstetrics and gynecology: associations with physicians' demographics and performances during medical schoolCynthia G Silber, J Jon Veloski
Academic Medicine : Journal of the Association of American Medical Colleges|May 29, 2004
Do global rating forms enable program directors to assess the ACGME competencies?Cynthia G Silber, Thomas J Nasca, David L Paskin, et al.
European Urology Oncology|July 10, 2021
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialBrian I Rini, Michael B Atkins, Elizabeth R Plimack, et al.
Pageof 1